Drug
Afamelanotide clinical trials
Also written CUV1647.
- studies test it
- 21
- open now
- 2
- in phase 3
- 5
- first study started
- 2007
Keep track of what changes. Save the afamelanotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 13
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 0
Clinuvel Pharmaceuticals Limited (16) · Clinuvel Europe Limited (3) · Clinuvel (UK) Ltd. (1) · Clinuvel, Inc. (1)
Studies
Open first, then newest update. How each study uses afamelanotide is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and VRecruitingPhase 2Clinuvel Europe LimitedNCT05370235Written as Afamelanotide
- A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)RecruitingPhase 2Clinuvel Europe LimitedNCT05159752Written as Afamelanotide
- Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria PatientsCompletedPhase 1/2Clinuvel Europe LimitedNCT06388642Written as Afamelanotide 16mg implant
- Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)CompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT05854784Written as Afamelanotide 16 MG
- Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)CompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT04525157Written as Afamelanotide
- A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)CompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT04962503Written as Afamelanotide
- DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy VolunteersCompletedPhase 1Clinuvel (UK) Ltd.NCT05368857Written as Afamelanotide
- A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the FaceStatus unknownPhase 2Clinuvel, Inc.NCT05210582Written as Afamelanotide
- Afamelanotide in Patients Suffering With Acne VulgarisCompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT04943159Written as Afamelanotide
- Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)CompletedPhase 3Clinuvel Pharmaceuticals LimitedNCT00979745Written as Afamelanotide
- Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer SodiumCompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT04425746Written as Afamelanotide
- Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)CompletedPhase 3Clinuvel Pharmaceuticals LimitedNCT04704713Written as Afamelanotide
- A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)CompletedPhase 3Clinuvel Pharmaceuticals LimitedNCT04578496Written as Afamelanotide
- Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)CompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT01097044Written as Afamelanotide
- Multicentre Phase III Erythropoietic Protoporphyria StudyCompletedPhase 3Clinuvel Pharmaceuticals LimitedNCT04053270Written as Afamelanotide
- Phase III Confirmatory Study in Erythropoietic ProtoporphyriaCompletedPhase 3Clinuvel Pharmaceuticals LimitedNCT01605136Written as Afamelanotide
- Implant Pharmacokinetic and Pharmacodynamic StudyCompletedPhase 1Clinuvel Pharmaceuticals LimitedNCT03634137Written as Afamelanotide Group 1
- Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental VitiligoCompletedPhase 2Clinuvel Pharmaceuticals LimitedNCT01382589Written as Afamelanotide
- Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)CompletedPhase 1Clinuvel Pharmaceuticals LimitedNCT01430195Written as Afamelanotide
- Phase II AK Study in Organ Transplant PatientsStatus unknownPhase 2Clinuvel Pharmaceuticals LimitedNCT00829192Written as Afamelanotide (CUV1647)
Codes
What other systems call afamelanotide · ClinicalTrials.gg INT005379
- MeSH (NLM) C534526afamelanotideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QW68W3J66UAFAMELANOTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 2262250One source FDA
- Wikidata Q410794afamelanotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82655AfamelanotideOne source FDA
- DrugBank DB04931One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C534526 | afamelanotide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QW68W3J66U | AFAMELANOTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262250 | — | One source FDA |
| Wikidata | Q410794 | afamelanotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82655 | Afamelanotide | One source FDA |
| DrugBank | DB04931 | — | One source Wikidata |
Also registered as afamelanotide acetate (UNII 1XCC161YKC · RxNorm 2278002).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.